[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486118":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":29,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":29,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":29,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":29,"overallStatus":38,"whyStopped":29,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Baylor College of Medicine","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Continued SRI","ACTIVE_COMPARATOR","After post-phase I assessment, participants who are eligible will be randomized to 1) Continued SRI. For these participants, the medication (SRI) will be provided at a consistent dosage.",[13],"Behavioral: Cognitive Behavioral Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Discontinuation titration to placebo","PLACEBO_COMPARATOR","After post-phase I assessment, participants who are eligible will be randomized to 2) Discontinuation titration to placebo. For these participants, the placebo substitution in an increasing proportion of capsules will be implemented until all drug is withdrawn.",[13],{"label":20,"type":6,"description":21,"interventionNames":22},"Open label CBT","During Phase I, all participants will receive open label cognitive-behavioral therapy. Only those who achieve significant benefit will be able to most on to the post-phase I assessment, and then to the random assignment to Continued SRI or Discontinuation titration to placebo arms.",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"BEHAVIORAL","Cognitive Behavioral Therapy","During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.\n\nDuring Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment.",[9,15,20],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Eric A Storch, Ph.D.","CONTACT","713-798-3080","eric.storch@bcm.edu",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Houston","Texas","77030","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-95.36327,29.76328,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":29,"phoneExt":29,"email":53},"Alyssa Hertz","alyssa.hertz@bcm.edu",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Eric A Storch","Professor","100486118","cbt-augmentation-to-promote-medication-discontinuation-in-pediatric-ocd-100486118",false,"NCT05609916","CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD","Inclusion Criteria:\n\n* The child is between the ages of 7 to 17 at enrollment with a primary diagnosis of OCD of \\> 6 months duration based on the Kiddie Schedule for Affective Disorders and Schizophrenia Lifetime Version for DSM-5 (KSADS-PL) and have a CY-BOCS ≥ 16.\n* The child is on stable and maximally tolerated SRI medication (i.e., clomipramine, fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram) for ≥12 weeks given that they are persistently and moderately symptomatic. Paroxetine is exclusionary due to safety concerns.\n* Both the child and parent participating in the study are English speaking.\n* Both the child and their parent participating in the study reside in Texas.\n\nExclusion Criteria:\n\n* The child has a diagnosis of lifetime DSM-5 bipolar disorder, psychotic disorder, and\u002For intellectual disability.\n* The child has severe current suicidal\u002Fhomicidal ideation and\u002For self-injury requiring medical intervention.\n* The child is receiving concurrent psychotherapy for OCD.\n* Initiation of a psychotropic medication less than 4 weeks prior to study enrollment or a stimulant\u002Fpsychoactive medication less than 2 weeks prior to study enrollment.","ALL","7 Years","17 Years",{"count":68,"type":69},200,"ESTIMATED","INTERVENTIONAL",[72],"NA","The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.",[26,75,76,77],"Obsessive-Compulsive Disorder","Obsessive-Compulsive Disorder in Children","Obsessive-Compulsive Disorder in Adolescence","2025-07-18",{"date":80,"type":81},"2025-07-20","ACTUAL",{"date":83,"type":81},"2022-11-30",{"date":85,"type":69},"2027-08-30",{"name":5,"class":6},1]